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cell lung cancer when tissue heterogeneity is
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Kazuhiro Tabata1,2, Tomonori Tanaka1,2, Tomayoshi Hayashi2, Takashi Hori3,4, Sayuri Nunomura1,2,
Suguru Yonezawa5 and Junya Fukuoka1,2*Abstract
Background: Ki-67 expression is a well-established prognostic marker in various cancers. However, Ki-67 expression
is also known as being heterogeneous. We investigated the prognostic significance of Ki-67 from the view of
staining heterogeneity by the technique of Spiral Array.
Methods: 100 cases of resected lung cancer from Toyama university hospital archive were collected. Spiral Array
blocks were generated out of 100 cases using 100 μm thick paraffin sections. Four μm thick sections of the Array
block were stained for Ki-67. Staining results in each reel were scored for areas with lowest (LS), highest (HS), and
average (AS) expression, exclusively in the cancer cells. Heterogeneity score (HeS) was designed as the difference
between HS and LS. The scores were divided into four grades (0–3). Clinical information was collected, and the
prognostic significance of Ki-67 was analyzed.
Results: Pathological stage was available for 91 patients (43 stage IA, 22 stage IB, 2 stage IIA, 9 stage IIB, 13 stage
IIIA, 1 stage IIIB, and 1 stage IV). The HS of Ki-67 score in non-small cell lung cancer was 3 in 17 cases, 2 in 27 cases,
1 in 28 cases, 0 in 21 cases, and 4 reels were lost. 78 cases had clinical follow up. 74 cases had all the information
available and were analyzed for correlation between Ki-67 expression and survival. Cases with score 2 and 3 of HS
and HeS showed significant poorer prognosis (both P < 0.001), whereas LS or AS did not show significance. The
results were identical when analyzing adenocarcinoma and squamous cell carcinoma, separately. Cox multivariate
analysis of Ki-67 showed that HS was an independent risk factor affecting overall survival.
Conclusions: Ki-67 is a strong prognostic marker for non-small cell lung cancer when the degree of highest
staining frequency or heterogeneity is considered.
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Lung cancer has the highest incidence and mortality of
major cancers throughout the world [1]. Stage is still the
most important prognostic factor and histology provides
limited prognostic value. Since outcomes can be differ-
ent even among patients with the same disease-stage, it
is important to evaluate additional factors that may help
to identify the patients with resectable tumors who are* Correspondence: fukuokaj@nagasaki-u.ac.jp
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unless otherwise stated.at high risk for recurrence and could consequently bene-
fit from adjuvant therapy. The proliferative rate has been
demonstrated to be a prognostic marker in some tu-
mors, and Ki-67 is a marker of proliferation associated
nuclear antigen expressed in replicating cells during all
phases of the cell cycle (G1, S, G2 and M), but not
expressed in quiescent (G0) cells [2]. The immunohisto-
chemical (IHC) expression of Ki-67 has been used for
the assessment of tumor proliferation, and high levels of
Ki-67 antigen have been reported to be associated with a
poor prognosis in many malignancies including those as-
sociated with carcinoma of the breast, prostate, bladderLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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within a given tumor limits might be in part respon-
sible for some controversial findings in the literature
[8,9]. Presence of tissue heterogeneity in each cancer
type may be clinically important. Therefore, hetero-
geneity should be evaluated separately for each cancer
type before extrapolating the results in clinical prac-
tice. Lung cancer is reported to be highly heteroge-
neous, and approximately 80 percent of adenocarcinoma
shows a mixed subtype [10]. The present investigation
aimed to evaluate the clinical significance of Ki-67 ex-
pression for predicting the prognosis in non-small cell
lung cancer (NSCLC) especially in regards to tissue
heterogeneity.
We have recently developed a novel technique, “Spiral
array”, in which each tissue array core consists of a
reeled layer of tissue cut as a horizontal section from the
donor block and not punching as a vertical cylinder core
[11]. Use of this Spiral Array technique gives us the
advantage of eliminating sampling bias due to repre-
sentation of different areas of the lesion by tumor
heterogeneity.
Ethics statement
This study was approved by the Institutional Review
Board of the Toyama university hospital (No.19-12).Figure 1 Schematic figure indicating composition process of Spiral A
B) The sections are then reeled on the plastic core. C) The subcylindric
reel was vertically inserted into a tissue-holding-cassette. E) By pouringMethods
Case selection
One hundred case of resected primary lung cancer with
the consent of patients and approval by internal review
board were collected from Toyama university hospital
archive based on the diagnosis and the quality of the
available tissue on the paraffin block. The specimens
were obtained through radical surgery, excisional biopsy
or tumor debulking. The hematoxylin and eosin (H&E)
slides from each case were reviewed and histologically
classified according to the 2004 WHO histological classi-
fication of Lung Cancer by TT and JF [12]. Clinical in-
formation including follow-up status, Brinkman index,
smoking history, and treatment of neoadjuvant or/and
adjuvant therapy were also gathered. On collecting this
cohort, we formed it anonymized.
Construction of spiral arrays
Formalin fixed paraffin embedded blocks from one
hundred cases of lung cancer were collected from the
pathology archives at Toyama University Hospital. Spiral
Arrays were constructed as reported [Figure 1] [11,13].
Spiral Arrays covers morphological variations included
in the one axis of the donor paraffin block, wider area
than conventional tissue microarrays, and addresses the
issue of tissue heterogeneity [Figure 2]. The blocks wererray. A) 100 μm-thick sections are cut from the donor blocks.
al cores were cut in the center of the reel. D) Each subcylindrical
a melted paraffin, Spiral Array block is completed.
Figure 2 Reflection of tissue heterogeneity by Spiral Array. A) Ki-67 immunohistochemical staining of lung adenocarcinoma shows variable
amounts of positive cells within the slide. Red line indicates the area of coverage inside the Spiral Array (bar = 5 mm). Both high expression area
of Ki-67 (B) and low expression area of Ki-67 (C) are included inside the same reel of Spiral Array.
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sections were cut with a standard microtome. From the
view of antigen preservation in the paraffin block, the
surface layers of the original blocks were discarded.
Then, the thick paraffin sections were applied to semi-
auto Spiral Array Constructor (Sakura Finetek Japan,
Tokyo). In the Array constructor, the sections were reeled
on the plastic core tubes of 3 mm diameter followed by
heating and cooling steps. The subcylinders were cut in
the center of the reels. Each subcylindrical reel was
vertically inserted into a tissue-holding-cassette made of
Acrylonitrile Butadiene Styrene polymer with 20 holes,
which are 3.3 mm diameter (Sakura Finetek Japan, Tokyo)
[Figure 1]. The plastic cassettes were placed on the metal
molds (Sakura Finetek Japan, Tokyo) where bottom sur-
face of the molds were covered by double sided adhe-
sive tapes. The edges of inserted subcylindrical reels
were adhered by the tape. Melted paraffin (Paraffin wax
II60, Sakura Finetek, Tokyo, Japan) at 65°C was poured
into the cassette to re-embed the reels, and was followed
by a cooling down period. Lastly, after removing the
molds and adhesive tape, the Spiral Array block was sec-
tioned at 4 μm.
Immunohistochemical staining
Four μm thick sections of the Array blocks were stained
with Ki-67. Immunohistochemical staining was performedusing Ventana Benchmark XT (Ventana, Tucson, AZ)
automated slide preparation system, and used a rabbit
monoclonal antibody to Ki-67 (clone 30–9, Ventana,
Tucson, AZ).
Scoring of the staining results and statistical analysis
The reels were first observed at low magnification for
determining the areas of highest and lowest expression
of Ki-67, and designated as Highest Score (HS) and
Lowest Score (LS), respectively. These areas were further
analyzed at a single high power field (HPF, 400× magni-
fication) and the staining scores were determined. Aver-
age of staining score in a whole reel was defined as
Average Score (AS). Ki-67 expression was defined as the
percent of Ki-67-positive tumor cells divided by the total
number of tumor cells within one HPF, and were divided
into four grades (0, < 1%; 1, 1-10%; 2, 11-30%; 3, > 30%)
[Figure 3], in which these cut-offs were determined by
the previous studies [14,15]. Level of tissue heterogeneity
was taken into considerations. Heterogeneity Score
(HeS) was defined as the difference between HS and LS
(HeS = HS-LS). The medical charts were reviewed and
clinical records including follow up data were collected.
Associations between clinico-pathological variables and
grading of Ki-67 scoring were analyzed using Chi-square
test for categorical variables and Wilcoxon test for
continuous variables. Survival probability was estimated
Figure 3 Grading of Ki-67 immunohistochemical staining on Spiral Array. Ki-67 positive ratio of tumor cells in a high power field (×400
magnification). Tumor cells with stained nucleus by the diaminobenzidine tetrahydrochloride, regardless their intensities, are count as positive.
A) Scanning view of the Spiral Array slide stained with Ki-67. (bar = 5 mm). B-D) Examples of reels showing Ki-67 staining of Grade 3, > 30%
(B); Grade 2, 11-30% (C); Grade 1, 1-10% (D). (bars in B, C, D = 100 μm).
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group comparison was performed using the log-rank test.
Uni- and multivariate analyses were performed using Cox
proportional-hazards regression models for age, gender,
stage, and HS. Statistical analyses were performed using
the JMP 10.0.2 statistical software (SAS institute, Inc.,




Patient demographics are summarized in Additional file
1. The patients with lung cancer consisted of 68 men
and 32 women, with ages ranging from 35 to 88 years
(mean 66.3 years) [Additional file 1]. Among the 100 pa-
tients with lung cancer, 44 patients died of lung cancer
(range of survival time: 6–156 months; mean 44.6 months),
34 were alive (range of follow-up time: 1–62 months,
mean 21.6 months), 2 died of other cause, and 20 were
lost from follow-up. As for the smoking history, 44 pa-
tients were former smokers, with 20 current smokers, 27
never smokers, and 9 cases with unknown smoking his-
tory. Pathological stage was available in 91 patients includ-
ing 43 stage IA, 22 stage IB, 2 stage IIA, 9 stage IIB, 13
stage IIIA, 1 stage IIIB, and 1 stage IV. Among 98 patients,
5 cases were treated with neoadjuvant therapy and 31cases were treated with adjuvant therapy. The information
about the surgical procedures was not available. The histo-
logic classification was as follows: 61 adenocarcinoma, 30
squamous cell carcinoma, 3 small cell carcinoma, 4 large
cell carcinoma, and 2 adenosquamous cell carcinoma.
From histopathological report, pleural invasion (68 pl0, 12
pl1, 1 pl2, 4 pl3, and 12 data not available), pulmonary
metastasis (64 pm0, 23 pm1, and 13 data not available),
lymphatic permeation (50 negative, 39 positive, and 11
data not available), and vascular invasion (61 negative, 29
positive, and 10 data not available) were identified.
Correlation between clinico-pathological variables and
Ki-67 scoring
In advance of scoring, 3 small cell carcinomas were
excluded from the candidate for evaluation. The HS in
Ki-67 staining was 17 score 3, 27 score 2, 28 score 1, 21
score 0, and 4 reels were worn [Table 1]. Several variables
including pathological T factor, pathological stage, and
vascular invasion had significant differences with HS of
Ki-67 scoring (P = 0.0051, 0.0384, 0.0265, respectively).
And pathological T factor, pathological N factor, patho-
logical stage, pleural invasion, and pulmonary metastasis
had significant differences with HeS (P < 0.0001, 0.0008,
0.0041, 0.0010, 0.0420, respectively) [Additional file 1].
LS and AS had no association with any of the variables
Table 1 Proportion of score in Ki-67 immunohistochemical
staining
HS HeS
0 1 2 3 0 1 2 3
NSCLC (n = 93) 21 28 27 17 30 36 24 3
ADC (n = 58) 17 20 16 5 23 23 13 0
SqCC (n = 27) 3 5 7 12 6 9 9 3
NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SqCC, squamous cell
carcinoma; HS, highest score; HeS, heterogeneity score.
Figure 4 Kaplan-Meier survival curves for non-small cell lung cancer (
(SqCC). Highest score (HS) 0–1 vs. HS 2–3 in NSCLC (A), in ADC (B), and in
groups. Heterogeneity score (HeS) 0–1 vs. HeS 2–3 in NSCLC (D), in AD
between the two groups. Lowest score (LS) 0–1 vs. LS 2–3 in NSCLC (
AS 2–3 (J) in NSCLC, (K) in ADC, (L) in SqCC do not show prognostic
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follow-up status. The cases analyzed with all of the data
were 74 cases.
Correlation of Ki-67 score with overall survival
HS, HeS, LS, and AS were respectively divided into two
category which were score 0 or 1 and score 2 or 3. Using
by Kaplan-Meier method, overall survival (OS) of pa-
tients with HS score 2 or 3 was evidently shorter thanNSCLC), adenocarcinoma (ADC), and squamous cell carcinoma
SqCC (C) show significant prognostic differences between the two
C (E), and in SqCC (F) also show significant prognostic differences
G), in ADC (H), and in SqCC (I) and Average score (AS) 0–1 vs.
differences between the two groups.
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(OS mean: HS ≧ 2, 29.4 months; HS < 2, 56.6 months;
P < 0.001) [Figure 4A]. In addition, the OS of patients
with HeS score 2 or 3 was also shorter than patients with
a score lower 2 with significance (OS mean: HeS ≧ 2,
21.4 months; HeS < 2, 52.7 months; P < 0.001) [Figure 4D],
whereas LS or AS did not show any significance in prog-
nostic value [Figure 4G-L]. The results were similar when
HS analysis was applied to ADC and SqCC separately
(P < 0.001 and 0.021, respectively) [Figure 4B,C], and
HeS analysis was applied to ADC and SqCC separately
(both P < 0.001) [Figure 4E,F]. Univariate analyses fitting
Cox proportional hazards model adjusted for stage
showed significance with OS in NSCLC, ADC, and SCC
(P < 0.0001, < 0.0001, 0.0055, respectively), and similarly,
there was a significant differences between HS and OS in
NSCLC, ADC, and SqCC (P < 0.0001, < 0.0001, 0.0002, re-
spectively) [Table 2]. In multivariate analyses, stage was
significantly associated with OS in NSCLC and ADC
(P = 0.0002, 0.0024, respectively), and HS had signifi-
cantly correlation with OS in NSCLC, ADC, and SqCC
(P = 0.0001, 0.0050, 0.0011, respectively). HS was consid-
ered to be an independent prognostic factor of OS in
NSCLC, ADC, and SqCC.
On collecting this cohort, we formed it anonymized.
Thus whole slide specimen corresponding the core of
Spiral Array was not available and we could not review
and reclassified ADC into histological subtypes in new
classification of lung adenocarcinoma proposed by Inter-
national Association for the Study of Lung Cancer
(IASLC). In SqCC, we could not evaluate the correlation
of Ki-67 expression with the differentiation of SqCC.Table 2 Uni- and multivariate analyses using Cox
proportional hazards model
Univariate Multivariate
HR P-value HR P-value
NSCLC (n = 74) Age 1.021 0.2997 1.014 0.5763
Gender 1.671 0.1864 1.431 0.3777
Stage 1.750 < 0.0001 1.432 0.0002
HS 8.702 < 0.0001 5.497 0.0001
ADC (n = 47) Age 1.033 0.2118 1.004 0.9044
Gender 1.489 0.3701 1.990 0.1633
Stage 15.614 < 0.0001 1.705 0.0024
HS 7.025 < 0.0001 4.424 0.0050
SqCC (n = 27) Age 0.999 0.9942 1.05 0.3197
Gender 1934 0.2834 1.048e + 10 0.2611
Stage 12.295 0.0055 1.188 0.3096
HS 1.41e + 9 0.0002 1.44e + 10 0.0011
NSCLC, non-small cell lung cancer; ADC, adenocarcinoma; SqCC, squamous cell
carcinoma; HS, highest score. Significant P-values are shown in Italics. P-values
from log-rank test.There is no significance between histopathological sub-
type, according to WHO classification in 2004, and HS
or HeS [Additional file 2].
Discussion
The correlation of Ki-67 labeling index with the progno-
sis of neoplasm is reported in many organs [3-7] including
lung cancer [14,16]. However, several studies revealed that
Ki-67 often fails to be an independent prognostic factor in
multivariate analyses [7,16]. And some reports in lung
cancer showed limited or negative association to progno-
sis [17,18]. Our study evidently showed that the highest
score (HS) of Ki-67 in NSCLC, ADC and SqCC had cor-
relation with OS by uni- and multivariate analyses. Dis-
cordance between previous reports and our results may
be due to the evaluation method of Ki-67 and tissue
heterogeneity. The meaningful evaluations of biomarkers
should be different by tumor types and biomarker. For
example, in breast cancer, overall average score is more
meaningful [19], in contrast, in neuroendocrine tu-
mors, scoring of highest positive density area shows more
benefits [20]. Our data that HS, not Average Score or
Lowest Score, only showed significant prognostic differ-
ence [Figure 4]. Needless to say, HS is the one that has the
strongest confounding nature with tissue heterogeneity.
Our data was obtained by new technique named Spiral
Array, which covers the morphological variations included
in one entire axis of the donor paraffin block [Figure 2].
Morphological consistency between the whole paraffin
section and Spiral Array was reported as reasonably
higher than conventional tissue microarray [11]. Our data
strongly indicates that inadequate scorings for Ki-67 easily
lose prognostic value for the tumor, which does have
reproducible and strong value by the different scoring
methods. Based on our results, it is suggested that the
Ki-67 scoring in hotspots, similar to the system pro-
posed in the neuroendocrine tumors may contribute
greatly in lung cancer, and overall average Ki-67 scoring
like the breast cancer system may not be appropriate.
Moreover, in order to take into account tissue heterogen-
eity, a larger sample might be necessary.
Our study also suggests that levels of tissue heterogeneity
(HeS) have correlation with OS (by univariate analysis).
Needless to say, our assessment for tissue heterogeneity
does not completely cover tissue heterogeneity in the
tumor. Potts et al. proposed the more precise method to
evaluate tissue heterogeneity by evaluating both cell-level
and tumor-level heterogeneity [21]. Compared to the study
in which they evaluated the heterogeneity of the protein
constantly expressed in the certain cellular location, the
marker like Ki-67 by its nature do not possess much im-
portance for the cell-level heterogeneity. Although our
HeS is still primitive, this surely shows a certain angle of
tissue heterogeneity for the marker like Ki-67. Importantly,
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clinic although HeS showed stronger prognostic value than
HS but think that HS is more applicable than HeS. How-
ever, the fact that higher tissue heterogeneity indicated the
poor prognostic impact is interesting. We think that may
indicate the presence of higher genetic variables inside the
one tumor, which may cause resistance to chemotherapy
and/or molecular targeted medicine. Effective and easy ap-
plicable way of analyzing tissue heterogeneity along with
its reproducible clinical impacts needs to be investigated in
the future.
Recently, some molecular markers, including the exci-
sion repair cross-complementation group 1 (ERCC1), ri-
bonucleotide reductase M1 (RRM1), epidermal growth
factor receptor (EGFR), and ROS1, were revealed as a
predictive marker for survival benefit and could also pre-
dict the effect of medical treatment [17,18,22]. However,
immunohistochemistry (IHC) of these markers are con-
troversial and have a limited use in larger institutions.
On the other hand, IHC of Ki-67 was distributed widely,
applied to various organs, and established for technique
and evaluation of IHC. In this point, IHC of Ki-67 is
more common and useful in routine work. Therefore,
we considered that evaluation of Ki-67 expression is still
important and the results of our study are significant.
Conclusion
Ki-67 is a strong prognostic marker for non-small cell
lung carcinoma when highest staining ratio or degree of
heterogeneity is considered. Consideration of tumor het-
erogeneity is important for the establishment of tissue-
based biomarkers.
Additional files
Additional file 1: Characteristics of all 100 lung cancer patients
used in this study and correlation with grades of Ki-67 score.
Additional file 2: Proportion of score in Ki-67 immunohistochemical
staining with 2004 WHO histological classification of Lung Cancer.
Competing interests
Dr. Fukuoka is a representative of a venture company, Pathology Institute
Corporation, founded inside Toyama University, and holds stock in the
company. Mr. Hori is a director of the same company and also holds stock in
the company.
Dr. Fukuoka and Mr. Hori received research funding of $235000 per annum
from Sakura Finetek Japan Co, Ltd, from November 2009 to October 2012.
This research was partly funded by the organization of Japan Science and
Technology Agency and Japanese Ministry of Health, Labor and Welfare.
No other authors have potential conflicts of interest related to the present
work.
Authors’ contributions
KT participated in the design of the study and performed the statistical
analysis, and made draft of the manuscript. TT and SN participated in the
collection of clinical information. TH and SY conceived of the study, and
participated in its design and coordination and helped to draft the
manuscript. TH participated in the selection of cases with Spiral Arrays. JF
designed the study, obtained the research funding, carried out the scoringof immunohistochemistry with Ki-67, and wrote the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
We thank Dr. Marcio Gomes, associate professor of the Division of
Anatomical Pathology, University of Ottawa for reviewing the manuscript,
and Drs. Sayaka Tominaga and Ryo Osawa, Ms. Noriko Kanamori for their
technical support.
Author details
1Department of Pathology, Nagasaki University Graduate School of
Biomedical Sciences, Nagasaki, Japan. 2Department of Pathology, Nagasaki
University Hospital, Nagasaki, Japan. 3Department of Surgical Pathology,
Laboratory of Pathology, Toyama, Japan. 4Department of Pathology, Toyama
University Hospital, 2630 Sugitani, Toyama 930-0194, Japan. 5Department of
Human Pathology, Field of Oncology, Kagoshima University Graduate School
of Medical and Dental Sciences, Kagoshima, Japan.
Received: 31 December 2013 Accepted: 2 May 2014
Published: 13 May 2014
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010,
127(12):2893–2917.
2. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle
analysis of a cell proliferation-associated human nuclear antigen defined
by the monoclonal antibody Ki-67. J immunol 1984, 133(4):1710–1715.
3. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P:
Proliferation index as a prognostic marker in breast cancer. Cancer 1993,
71(12):3926–3931.
4. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M: Expression of
potential molecular markers in prostate cancer: correlation with
clinicopathological outcomes in patients undergoing radical
prostatectomy. Urol Oncol 2010, 28(2):145–151.
5. Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Tetu B, Meyer F,
Fradet Y: Prognostic value of the proliferative index determined by
Ki-67 immunostaining in superficial bladder tumors. Hum Pathol 1999,
30(11):1350–1355.
6. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O: Ki-67 expression in axillary
lymph node metastases in breast cancer is prognostically significant.
Hum Pathol 2013, 44(1):39–46.
7. Jamali M, Chetty R: Predicting prognosis in gastroentero-pancreatic
neuroendocrine tumors: an overview and the value of Ki-67
immunostaining. Endocr Pathol 2008, 19(4):282–288.
8. Macdonald C, Michael A, Colston K, Mansi J: Heterogeneity of
immunostaining for tumour markers in non-small cell lung carcinoma.
European J Cancer 2004, 40(3):461–466.
9. Couvelard A, Deschamps L, Ravaud P, Baron G, Sauvanet A, Hentic O,
Colnot N, Paradis V, Belghiti J, Bedossa P, Ruszniewski P: Heterogeneity of
tumor prognostic markers: a reproducibility study applied to liver
metastases of pancreatic endocrine tumors. Mod Pathol: an official Jof the
United States and Canadian Academy of Pathology, Inc 2009, 22(2):273–281.
10. Terasaki H, Niki T, Matsuno Y, Yamada T, Maeshima A, Asamura H,
Hayabuchi N, Hirohashi S: Lung adenocarcinoma with mixed
bronchioloalveolar and invasive components: clinicopathological
features, subclassification by extent of invasive foci, and
immunohistochemical characterization. Am J Surg Pathol 2003,
27(7):937–951.
11. Fukuoka J, Hofer MD, Hori T, Tanaka T, Ishizawa S, Nomoto K, Saito M,
Uemura T, Chirieac LR: Spiral array: a new high-throughput technology
covers tissue heterogeneity. Arch Pathol Lab Med 2012, 136(11):1377–1384.
12. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds): Patohology and
Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press;
2004.
13. Komiya A, Kato T, Hori T, Fukuoka J, Yasuda K, Fuse H, Komiya A, Kato T,
Hori T, Fukuoka J, Yasuda K, Fuse H: Application of a new technique,
spiral tissue microarrays constructed using needle biopsy specimens,
to prostate cancer research. Int J Oncol 2014, 44(1):195–202.
14. Haga Y, Hiroshima K, Iyoda A, Shibuya K, Shimamura F, Iizasa T, Fujisawa T,
Ohwada H: Ki-67 expression and prognosis for smokers with resected
Tabata et al. BMC Clinical Pathology 2014, 14:23 Page 8 of 8
http://www.biomedcentral.com/1472-6890/14/23stage I non-small cell lung cancer. Ann Thorac Surg 2003, 75(6):1727–1732.
discussion 1732–1723.
15. Hommura F, Dosaka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H,
Ogura S, Shimizu M, Katoh H, Kawakami Y: Prognostic significance of
p27KIP1 protein and ki-67 growth fraction in non-small cell lung
cancers. Clin Cancer Res 2000, 6(10):4073–4081.
16. Inoue M, Takakuwa T, Minami M, Shiono H, Utsumi T, Kadota Y, Nasu T,
Aozasa K, Okumura M: Clinicopathologic factors influencing postoperative
prognosis in patients with small-sized adenocarcinoma of the lung.
J Thorac Cardiovas Surg 2008, 135(4):830–836.
17. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N,
Sekine I, Kunitoh H, Furuta K, Tamura T: EGFR mutations predict survival
benefit from gefitinib in patients with advanced lung adenocarcinoma:
a historical comparison of patients treated before and after gefitinib
approval in Japan. J Clin Oncol: official journal of the American Society of
Clinical Oncology 2008, 26(34):5589–5595.
18. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT,
Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H,
Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-
Kenudson M, Pao W, Iafrate AJ: ROS1 rearrangements define a unique
molecular class of lung cancers. J Clin Oncol 2012, 30(8):863–870.
19. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M,
Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L,
Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF,
International Ki-67 in Breast Cancer Working G: Assessment of Ki67 in
breast cancer: recommendations from the International Ki67 in Breast
Cancer working group. J Nat Cancer Inst 2011, 103(22):1656–1664.
20. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S: The pathologic
classification of neuroendocrine tumors: a review of nomenclature,
grading, and staging systems. Pancreas 2010, 39(6):707–712.
21. Potts SJ, Krueger JS, Landis ND, Eberhard DA, Young GD, Schmechel SC,
Lange H: Evaluating tumor heterogeneity in immunohistochemistry-
stained breast cancer tissue. Lab Invest 2012, 92(9):1342–1357.
22. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G: DNA synthesis and
repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007,
356(8):800–808.
doi:10.1186/1472-6890-14-23
Cite this article as: Tabata et al.: Ki-67 is a strong prognostic marker of
non-small cell lung cancer when tissue heterogeneity is considered.
BMC Clinical Pathology 2014 14:23.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
